Cite
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
MLA
Louis, Edouard, et al. “Withdrawal of Infliximab or Concomitant Immunosuppressant Therapy in Patients with Crohn’s Disease on Combination Therapy (SPARE): A Multicentre, Open-Label, Randomised Controlled Trial.” The Lancet Gastroenterology & Hepatology, vol. 8, no. 3, Mar. 2023, pp. 215–27. EBSCOhost, https://doi.org/10.1016/S2468-1253(22)00385-5.
APA
Louis, E., Resche-Rigon, M., Laharie, D., Satsangi, J., Ding, N., Siegmund, B., D’Haens, G., Picon, L., Bossuyt, P., Vuitton, L., Irving, P., Viennot, S., Lamb, C. A., Pollok, R., Baert, F., Nachury, M., Fumery, M., Gilletta, C., Almer, S., … Roblin, X. (2023). Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 8(3), 215–227. https://doi.org/10.1016/S2468-1253(22)00385-5
Chicago
Louis, Edouard, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D’Haens, et al. 2023. “Withdrawal of Infliximab or Concomitant Immunosuppressant Therapy in Patients with Crohn’s Disease on Combination Therapy (SPARE): A Multicentre, Open-Label, Randomised Controlled Trial.” The Lancet Gastroenterology & Hepatology 8 (3): 215–27. doi:10.1016/S2468-1253(22)00385-5.